EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma

Ziyi Peng, Jingya Wang, Jing Guo, Xin Li, Sheng Wang, Ying Xie, Hongmei Jiang, Yixuan Wang, Mengqi Wang, Meilin Hu, Qian Li, Yafei Wang und 2 weitere

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2022-006325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Ziyi Peng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Receptors, Retinoic Acid, Multiple Myeloma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Guangci Translational Medicine Research Foundation, National Natural Science Foundation of China, Beijing Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapies targeting CD38 have demonstrated salient efficacy in relapsed/refractory multiple myeloma (MM). However, loss of CD38 antigen and outgrowth of CD38 negative plasma cells have emerged as a major obstacle in clinics. All-trans retinoic acid (ATRA) has been reported to upregulate CD38 expression, but the mechanism and adaptive genetic background remain unexplored.

Methods

The efficacy of ATRA in upregulating CD38 expression in MM cells is evaluated by flow cytometry. The interaction between NSD2 and the RARα is analyzed by immunoprecipitation, and the nuclear condensation of RARα is evaluated under laser confocal microscope. A graft model of MM is established in NOD. Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice, and the tumor burden is assessed by in vivo fluorescence imaging.

Results

We report that ATRA upregulates MM cells CD38 in a non-linear manner, which is t(4;14) translocation dependent, and t(4;14) translocation-induced NSD2 shows positive correlation with ATRA-induced level of, but not with basal level of CD38 expression. Mechanistically, NSD2 interacts with the ATRA receptor, RARα, and protects it from degradation. Meanwhile, NSD2 enhances the nuclear condensation of RARα and modifies the histone H3 dimethylation at lysine 36 on CD38 promoter. Knockdown of NSD2 attenuates the sensitization of MM against ATRA induced CD38 upregulation. Translationally, ATRA is prone to augment the efficacy of anti-CD38 CAR T cells in NSD2 high MM cells in vitro and in vivo.

Conclusion

This study elucidates a mechanism of ATRA in regulating CD38 expression and expands the clinical potential of ATRA in improving immunotherapies against CD38 in patients with MM.Cite Now

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Retinoic AcidMultiple MyelomaMiceAnimalsImmunotherapy, AdoptiveMice, Inbred NODTretinoinRetinoic Acid Receptor alpha

Stichwörter der Autor:innen

immunotherapy

Substanzen

Receptors, Retinoic AcidTretinoinRetinoic Acid Receptor alpha

Autor:innen und Institutionen

  • Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China.
  • Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
  • Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
  • School of Stomatology, Tianjin Medical University, Tianjin, China.
  • School of Medicine, Shanghai Jiao Tong University, Shanghai, China zhiqiangliu@tmu.edu.cn jianqingmi@shsmu.edu.cn.
  • Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China zhiqiangliu@tmu.edu.cn jianqingmi@shsmu.edu.cn.

ORCID-Profile: Zhiqiang Liu

Förderung

  • Shanghai Guangci Translational Medicine Research Foundation
  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation of China

Zitieren

APA

Peng, Z., Wang, J., Guo, J., Li, X., Wang, S., Xie, Y., Jiang, H., Wang, Y., Wang, M., Hu, M., Li, Q., Wang, Y., Mi, J. Q., & Liu, Z. (2023). All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006325

Vancouver

Peng Z, Wang J, Guo J, Li X, Wang S, Xie Y, et al. All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006325

BibTeX
@article{Peng2023,
  author = {Peng, Ziyi and Wang, Jingya and Guo, Jing and Li, Xin and Wang, Sheng and Xie, Ying and Jiang, Hongmei and Wang, Yixuan and Wang, Mengqi and Hu, Meilin and Li, Qian and Wang, Yafei and Mi, Jian-Qing and Liu, Zhiqiang},
  title = {All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2022-006325}
}
Kostenlos starten →